{
    "clinical_study": {
        "@rank": "61969", 
        "arm_group": [
            {
                "arm_group_label": "GSK2282512A Group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of quadrivalent influenza GSK2282512A vaccine.\nQuadrivalent influenza GSK2282512A vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects \u2265 12 months of age)."
            }, 
            {
                "arm_group_label": "Fluarix Group", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Fluarix vaccine.\nFluarix vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects \u2265 12 months of age)."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the immunogenicity, reactogenicity and safety of\n      the new influenza vaccine GSK2282512A (FLU-Q-QIV) and compare its activity to the marketed\n      vaccine Fluarix\u00ae (TIV) in young children 6 to 35 months of age."
        }, 
        "brief_title": "Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children 6 to 35 Months of Age", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": [
                        {
                            "@group_id": "B1", 
                            "description": "Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of quadrivalent influenza GSK2282512A vaccine.\nQuadrivalent influenza GSK2282512A vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects \u2265 12 months of age).", 
                            "title": "GSK2282512A Group"
                        }, 
                        {
                            "@group_id": "B2", 
                            "description": "Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Fluarix vaccine.\nFluarix vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects \u2265 12 months of age).", 
                            "title": "Fluarix Group"
                        }, 
                        {
                            "@group_id": "B3", 
                            "description": "Total of all reporting groups", 
                            "title": "Total"
                        }
                    ]
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": [
                                            {
                                                "@group_id": "B1", 
                                                "@value": "299"
                                            }, 
                                            {
                                                "@group_id": "B2", 
                                                "@value": "302"
                                            }, 
                                            {
                                                "@group_id": "B3", 
                                                "@value": "601"
                                            }
                                        ]
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": [
                                            {
                                                "@group_id": "B1", 
                                                "@spread": "8.17", 
                                                "@value": "18.2"
                                            }, 
                                            {
                                                "@group_id": "B2", 
                                                "@spread": "8.34", 
                                                "@value": "18.1"
                                            }, 
                                            {
                                                "@group_id": "B3", 
                                                "@spread": "8.25", 
                                                "@value": "18.15"
                                            }
                                        ]
                                    }
                                }
                            }, 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Age", 
                            "units": "Months"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": [
                                                {
                                                    "@group_id": "B1", 
                                                    "@value": "155"
                                                }, 
                                                {
                                                    "@group_id": "B2", 
                                                    "@value": "146"
                                                }, 
                                                {
                                                    "@group_id": "B3", 
                                                    "@value": "301"
                                                }
                                            ]
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": [
                                                {
                                                    "@group_id": "B1", 
                                                    "@value": "144"
                                                }, 
                                                {
                                                    "@group_id": "B2", 
                                                    "@value": "156"
                                                }, 
                                                {
                                                    "@group_id": "B3", 
                                                    "@value": "300"
                                                }
                                            ]
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "Subjects"
                        }
                    ]
                }
            }, 
            "certain_agreements": {
                "pi_employee": "Principal Investigators are NOT employed by the organization sponsoring the study.", 
                "restrictive_agreement": "GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."
            }, 
            "outcome_list": {
                "outcome": [
                    {
                        "description": "A seroconverted subject was defined as a vaccinated subject with either a pre-vaccination titer less than (<) 1:10 and a post-vaccination titer greater than or equal to (\u2265) 1:40, or a pre-vaccination titer \u2265 1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains assessed were Flu A/CAL/7/09 (H1N1), Flu A/Victoria/361/11 (H3N2), Flu B/Hubei-Wujiagang/158/09 (Yamagata) and Flu B/Bri/60/08 (Victoria). This outcome concerns solely subjects in the GSK2282512A Group.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of quadrivalent influenza GSK2282512A vaccine.\nQuadrivalent influenza GSK2282512A vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects \u2265 12 months of age).", 
                                "title": "GSK2282512A Group"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "284"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "244"
                                                    }
                                                }, 
                                                "sub_title": "[H1N1, Day 28 = primed and Day 56 = unprimed]"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "205"
                                                    }
                                                }, 
                                                "sub_title": "[H3N2, Day 28 = primed and Day 56 = unprimed]"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "224"
                                                    }
                                                }, 
                                                "sub_title": "[Yamagata, Day 28 = primed and Day 56 = unprimed]"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "210"
                                                    }
                                                }, 
                                                "sub_title": "[Victoria, Day 28 = primed and Day 56 = unprimed]"
                                            }
                                        ]
                                    }, 
                                    "description": "A seroconverted subject was defined as a vaccinated subject with either a pre-vaccination titer less than (<) 1:10 and a post-vaccination titer greater than or equal to (\u2265) 1:40, or a pre-vaccination titer \u2265 1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains assessed were Flu A/CAL/7/09 (H1N1), Flu A/Victoria/361/11 (H3N2), Flu B/Hubei-Wujiagang/158/09 (Yamagata) and Flu B/Bri/60/08 (Victoria). This outcome concerns solely subjects in the GSK2282512A Group.", 
                                    "param": "Number", 
                                    "title": "Number of Seroconverted Subjects for Anti- Haemagglutination Inhibition (HI) Antibodies Against Each of the Four Vaccine Influenza Strains of Quadrivalent Influenza GSK2282512A Vaccine.", 
                                    "units": "subjects"
                                }
                            ]
                        }, 
                        "population": "The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, in terms of antibody response measured by the Haemagglutination Inhibition assay, included all evaluable subjects for whom data concerning immunogenicity outcome measures were available.", 
                        "safety_issue": "No", 
                        "time_frame": "At Day 28 for primed subjects and at Day 56 for unprimed subjects", 
                        "title": "Number of Seroconverted Subjects for Anti- Haemagglutination Inhibition (HI) Antibodies Against Each of the Four Vaccine Influenza Strains of Quadrivalent Influenza GSK2282512A Vaccine.", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Solicited local symptoms assessed were pain, redness and swelling. Any was defined as occurrence of the specified solicited local symptom regardless of its intensity. Grade 3 pain was defined as pain that prevented normal everyday activities. Grade 3 swelling was greater than 100 millimeters (mm) i.e. >100mm.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of quadrivalent influenza GSK2282512A vaccine.\nQuadrivalent influenza GSK2282512A vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects \u2265 12 months of age).", 
                                    "title": "GSK2282512A Group"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Fluarix vaccine.\nFluarix vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects \u2265 12 months of age).", 
                                    "title": "Fluarix Group"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "291"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "297"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "95"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "91"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Any Pain"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "7"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "3"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Grade 3 Pain"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "6"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "6"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Any Redness"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "0"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Grade 3 Redness"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "5"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "6"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Any Swelling"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "0"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Grade 3 Swelling"
                                            }
                                        ]
                                    }, 
                                    "description": "Solicited local symptoms assessed were pain, redness and swelling. Any was defined as occurrence of the specified solicited local symptom regardless of its intensity. Grade 3 pain was defined as pain that prevented normal everyday activities. Grade 3 swelling was greater than 100 millimeters (mm) i.e. >100mm.", 
                                    "param": "Number", 
                                    "title": "Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms.", 
                                    "units": "subjects"
                                }
                            ]
                        }, 
                        "population": "The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented.", 
                        "safety_issue": "No", 
                        "time_frame": "During the 7-day (Days 0-6) post-vaccination period", 
                        "title": "Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms.", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Solicited general symptoms assessed were drowsiness, irritability/fussiness and loss of appetite. Any was defined as any solicited general symptom reported irrespective of intensity and relationship to vaccination. Related was defined as symptoms assessed by the investigator to have a causal relationship to vaccination. Grade 3 irritability/fussiness was defined as crying that could not be comforted/prevented normal activity. Grade 3 loss of appetite was defined as not eating at all. Grade 3 drowsiness was defined as drowsiness that prevented normal activity.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of quadrivalent influenza GSK2282512A vaccine.\nQuadrivalent influenza GSK2282512A vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects \u2265 12 months of age).", 
                                    "title": "GSK2282512A Group"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Fluarix vaccine.\nFluarix vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects \u2265 12 months of age).", 
                                    "title": "Fluarix Group"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "290"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "296"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "93"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "88"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Any Drowsiness"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "9"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "9"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Grade 3 Drowsiness"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "79"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "80"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Related Drowsiness"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "118"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "123"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Any Irritability/fussiness"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "15"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "14"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Grade 3 Irritability/fussiness"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "104"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "106"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Related Irritability/fussiness"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "99"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "100"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Any Loss of appetite"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "16"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "14"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Grade 3 Loss of appetite"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "84"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "83"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Related Loss of appetite"
                                            }
                                        ]
                                    }, 
                                    "description": "Solicited general symptoms assessed were drowsiness, irritability/fussiness and loss of appetite. Any was defined as any solicited general symptom reported irrespective of intensity and relationship to vaccination. Related was defined as symptoms assessed by the investigator to have a causal relationship to vaccination. Grade 3 irritability/fussiness was defined as crying that could not be comforted/prevented normal activity. Grade 3 loss of appetite was defined as not eating at all. Grade 3 drowsiness was defined as drowsiness that prevented normal activity.", 
                                    "param": "Number", 
                                    "title": "Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms (Excluding Fever).", 
                                    "units": "subjects"
                                }
                            ]
                        }, 
                        "population": "The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented.", 
                        "safety_issue": "No", 
                        "time_frame": "During the 7-day (Days 0-6) post-vaccination period", 
                        "title": "Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms (Excluding Fever).", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Any fever was defined as any fever \u226538.0 degrees Celsius (\u00b0C) irrespective of intensity and relationship to vaccination. Related was defined as symptoms assessed by the investigator to have a causal relationship to vaccination. Grade 3 fever was defined as fever \u226539.0 \u00b0C.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of quadrivalent influenza GSK2282512A vaccine.\nQuadrivalent influenza GSK2282512A vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects \u2265 12 months of age).", 
                                    "title": "GSK2282512A Group"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Fluarix vaccine.\nFluarix vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects \u2265 12 months of age).", 
                                    "title": "Fluarix Group"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "290"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "296"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "61"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "60"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Any Fever"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "23"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "13"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Grade 3 Fever"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "49"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "48"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Related Fever"
                                            }
                                        ]
                                    }, 
                                    "description": "Any fever was defined as any fever \u226538.0 degrees Celsius (\u00b0C) irrespective of intensity and relationship to vaccination. Related was defined as symptoms assessed by the investigator to have a causal relationship to vaccination. Grade 3 fever was defined as fever \u226539.0 \u00b0C.", 
                                    "param": "Number", 
                                    "title": "Number of Subjects Reporting Any, Grade 3 and Related Fever", 
                                    "units": "subjects"
                                }
                            ]
                        }, 
                        "population": "The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented.", 
                        "safety_issue": "No", 
                        "time_frame": "During the 7-day (Days 0-6) post-vaccination period", 
                        "title": "Number of Subjects Reporting Any, Grade 3 and Related Fever", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "HI antibody titres were expressed as Geometric mean titers (GMTs). The vaccine strains assessed were Flu A/CAL/7/09 (H1N1), Flu A/Victoria/361/11 (H3N2), Flu B/Hubei-Wujiagang/158/09 (Yamagata) and Flu B/Bri/60/08 (Victoria)", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of quadrivalent influenza GSK2282512A vaccine.\nQuadrivalent influenza GSK2282512A vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects \u2265 12 months of age).", 
                                    "title": "GSK2282512A Group"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Fluarix vaccine.\nFluarix vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects \u2265 12 months of age).", 
                                    "title": "Fluarix Group"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "284"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "287"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "8.1", 
                                                            "@upper_limit": "11.3", 
                                                            "@value": "9.6"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "8.3", 
                                                            "@upper_limit": "11.6", 
                                                            "@value": "9.8"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "[H1N1, Day 0]"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "132.8", 
                                                            "@upper_limit": "185.9", 
                                                            "@value": "157.1"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "49.2", 
                                                            "@upper_limit": "76.2", 
                                                            "@value": "61.2"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "[H1N1, Day 28 = primed and Day 56 = unprimed]"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "14.1", 
                                                            "@upper_limit": "21.5", 
                                                            "@value": "17.4"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "11.4", 
                                                            "@upper_limit": "16.8", 
                                                            "@value": "13.8"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "[H3N2, Day 0]"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "129.4", 
                                                            "@upper_limit": "196.3", 
                                                            "@value": "159.4"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "83.7", 
                                                            "@upper_limit": "126.7", 
                                                            "@value": "103.0"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "[H3N2, Day 28 = primed and Day 56 = unprimed]"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "6.9", 
                                                            "@upper_limit": "8.7", 
                                                            "@value": "7.7"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "6.5", 
                                                            "@upper_limit": "8.0", 
                                                            "@value": "7.2"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "[Yamagata, Day 0]"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "100.0", 
                                                            "@upper_limit": "130.5", 
                                                            "@value": "114.2"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "92.2", 
                                                            "@upper_limit": "124.6", 
                                                            "@value": "107.2"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "[Yamagata, Day 28 = primed and Day 56 = unprimed]"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "9.1", 
                                                            "@upper_limit": "12.4", 
                                                            "@value": "10.6"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "8.0", 
                                                            "@upper_limit": "10.7", 
                                                            "@value": "9.3"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "[Victoria, Day 0]"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "91.9", 
                                                            "@upper_limit": "135.2", 
                                                            "@value": "111.4"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "13.3", 
                                                            "@upper_limit": "18.5", 
                                                            "@value": "15.6"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "[Victoria, Day 28 = primed and Day 56 = unprimed]"
                                            }
                                        ]
                                    }, 
                                    "description": "HI antibody titres were expressed as Geometric mean titers (GMTs). The vaccine strains assessed were Flu A/CAL/7/09 (H1N1), Flu A/Victoria/361/11 (H3N2), Flu B/Hubei-Wujiagang/158/09 (Yamagata) and Flu B/Bri/60/08 (Victoria)", 
                                    "dispersion": "95% Confidence Interval", 
                                    "param": "Geometric Mean", 
                                    "title": "Haemagglutination Inhibition (HI) Antibody Titers Against Each of the Four Vaccine Influenza Strains", 
                                    "units": "Titers"
                                }
                            ]
                        }, 
                        "population": "The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, in terms of antibody response measured by the Haemagglutination Inhibition assay, included all evaluable subjects for whom data concerning immunogenicity outcome measures were available.", 
                        "safety_issue": "No", 
                        "time_frame": "At Day 0 (for all subjects) and 28 days after the last vaccine dose (at Day 28 for primed subjects and at Day 56 for unprimed subjects)", 
                        "title": "Haemagglutination Inhibition (HI) Antibody Titers Against Each of the Four Vaccine Influenza Strains", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "A seroconverted subject was defined as a vaccinated subject with either a pre-vaccination titer less than (<) 1:10 and a post-vaccination titer greater than or equal to (\u2265) 1:40, or a pre-vaccination titer \u2265 1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains assessed were Flu A/CAL/7/09 (H1N1), Flu A/Victoria/361/11 (H3N2), Flu B/Hubei-Wujiagang/158/09 (Yamagata) and Flu B/Bri/60/08 (Victoria). This outcome concerns solely subjects in the Fluarix Group.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Fluarix vaccine.\nFluarix vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects \u2265 12 months of age).", 
                                "title": "Fluarix Group"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "287"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "154"
                                                    }
                                                }, 
                                                "sub_title": "[H1N1, Day 28 = primed and Day 56 = unprimed]"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "160"
                                                    }
                                                }, 
                                                "sub_title": "[H3N2, Day 28 = primed and Day 56 = unprimed]"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "222"
                                                    }
                                                }, 
                                                "sub_title": "[Yamagata, Day 28 = primed and Day 56 = unprimed]"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "28"
                                                    }
                                                }, 
                                                "sub_title": "[Victoria, Day 28 = primed and Day 56 = unprimed]"
                                            }
                                        ]
                                    }, 
                                    "description": "A seroconverted subject was defined as a vaccinated subject with either a pre-vaccination titer less than (<) 1:10 and a post-vaccination titer greater than or equal to (\u2265) 1:40, or a pre-vaccination titer \u2265 1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains assessed were Flu A/CAL/7/09 (H1N1), Flu A/Victoria/361/11 (H3N2), Flu B/Hubei-Wujiagang/158/09 (Yamagata) and Flu B/Bri/60/08 (Victoria). This outcome concerns solely subjects in the Fluarix Group.", 
                                    "param": "Number", 
                                    "title": "Number of Seroconverted Subjects for Anti- Haemagglutination Inhibition (HI) Antibodies Against Each of the Four Vaccine Influenza Strains of Fluarix Vaccine", 
                                    "units": "subjects"
                                }
                            ]
                        }, 
                        "population": "The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, in terms of antibody response measured by the Haemagglutination Inhibition assay, included all evaluable subjects for whom data concerning immunogenicity outcome measures were available.", 
                        "safety_issue": "No", 
                        "time_frame": "At Day 28 for primed subjects and at Day 56 for unprimed subjects", 
                        "title": "Number of Seroconverted Subjects for Anti- Haemagglutination Inhibition (HI) Antibodies Against Each of the Four Vaccine Influenza Strains of Fluarix Vaccine", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "A seroprotected subject was defined as a vaccinated subject with a serum HI titer greater than or equal to (\u2265) 1:40 that usually is accepted as indicating protection in adults. The vaccine strains assessed were Flu A/CAL/7/09 (H1N1), Flu A/Victoria/361/11 (H3N2), Flu B/Hubei-Wujiagang/158/09 (Yamagata) and Flu B/Bri/60/08 (Victoria)", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of quadrivalent influenza GSK2282512A vaccine.\nQuadrivalent influenza GSK2282512A vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects \u2265 12 months of age).", 
                                    "title": "GSK2282512A Group"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Fluarix vaccine.\nFluarix vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects \u2265 12 months of age).", 
                                    "title": "Fluarix Group"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "284"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "287"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "46"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "47"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "[H1N1, Day 0]"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "254"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "169"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "[H1N1, Day 28 = primed and Day 56 = unprimed]"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "93"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "74"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "[H3N2, Day 0]"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "231"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "191"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "[H3N2, Day 28 = primed and Day 56 = unprimed]"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "26"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "24"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "[Yamagata, Day 0]"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "242"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "229"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "[Yamagata, Day 28 = primed and Day 56 = unprimed]"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "56"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "45"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "[Victoria, Day 0]"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "216"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "74"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "[Victoria, Day 28 = primed and Day 56 = unprimed]"
                                            }
                                        ]
                                    }, 
                                    "description": "A seroprotected subject was defined as a vaccinated subject with a serum HI titer greater than or equal to (\u2265) 1:40 that usually is accepted as indicating protection in adults. The vaccine strains assessed were Flu A/CAL/7/09 (H1N1), Flu A/Victoria/361/11 (H3N2), Flu B/Hubei-Wujiagang/158/09 (Yamagata) and Flu B/Bri/60/08 (Victoria)", 
                                    "param": "Number", 
                                    "title": "Number of Subjects Who Were Seroprotected for Haemagglutination Inhibition (HI) Antibodies Against Each of the Four Vaccine Influenza Strains.", 
                                    "units": "subjects"
                                }
                            ]
                        }, 
                        "population": "The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, in terms of antibody response measured by the Haemagglutination Inhibition assay, included all evaluable subjects for whom data concerning immunogenicity outcome measures were available.", 
                        "safety_issue": "No", 
                        "time_frame": "At Day 0 (for all subjects) and Day 28 after last vaccine dose (Day 28 for primed subjects and Day 56 for unprimed subjects)", 
                        "title": "Number of Subjects Who Were Seroprotected for Haemagglutination Inhibition (HI) Antibodies Against Each of the Four Vaccine Influenza Strains.", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "MGI was defined as the fold increase in serum haemagglutination inhibition (HI) GMTs post-vaccination compared to pre-vaccination (Day 0). The vaccine strains assessed were Flu A/CAL/7/09 (H1N1), Flu A/Victoria/361/11 (H3N2), Flu B/Hubei-Wujiagang/158/09 (Yamagata) and Flu B/Bri/60/08 (Victoria)", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of quadrivalent influenza GSK2282512A vaccine.\nQuadrivalent influenza GSK2282512A vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects \u2265 12 months of age).", 
                                    "title": "GSK2282512A Group"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Fluarix vaccine.\nFluarix vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects \u2265 12 months of age).", 
                                    "title": "Fluarix Group"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "284"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "287"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "14.3", 
                                                            "@upper_limit": "18.7", 
                                                            "@value": "16.4"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "5.3", 
                                                            "@upper_limit": "7.3", 
                                                            "@value": "6.2"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "[H1N1, Day 28 = primed and Day 56 = unprimed]"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "8.0", 
                                                            "@upper_limit": "10.5", 
                                                            "@value": "9.1"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "6.4", 
                                                            "@upper_limit": "8.7", 
                                                            "@value": "7.5"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "[H3N2, Day 28 = primed and Day 56 = unprimed]"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "12.8", 
                                                            "@upper_limit": "17.1", 
                                                            "@value": "14.8"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "12.8", 
                                                            "@upper_limit": "17.2", 
                                                            "@value": "14.8"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "[Yamagata, Day 28 = primed and Day 56 = unprimed]"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@lower_limit": "9.2", 
                                                            "@upper_limit": "11.9", 
                                                            "@value": "10.5"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@lower_limit": "1.5", 
                                                            "@upper_limit": "1.9", 
                                                            "@value": "1.7"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "[Victoria, Day 28 = primed and Day 56 = unprimed]"
                                            }
                                        ]
                                    }, 
                                    "description": "MGI was defined as the fold increase in serum haemagglutination inhibition (HI) GMTs post-vaccination compared to pre-vaccination (Day 0). The vaccine strains assessed were Flu A/CAL/7/09 (H1N1), Flu A/Victoria/361/11 (H3N2), Flu B/Hubei-Wujiagang/158/09 (Yamagata) and Flu B/Bri/60/08 (Victoria)", 
                                    "dispersion": "95% Confidence Interval", 
                                    "param": "Geometric Mean", 
                                    "title": "Mean Geometric Increase (MGI) for Haemagglutination Inhibition (HI) Antibody Titer Against Each of the Four Vaccine Influenza Strains.", 
                                    "units": "Fold increase"
                                }
                            ]
                        }, 
                        "population": "The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, in terms of antibody response measured by the Haemagglutination Inhibition assay, included all evaluable subjects for whom data concerning immunogenicity outcome measures were available.", 
                        "safety_issue": "No", 
                        "time_frame": "28 days after the last vaccine dose (at Day 28 for primed subjects and at Day 56 for unprimed subjects)", 
                        "title": "Mean Geometric Increase (MGI) for Haemagglutination Inhibition (HI) Antibody Titer Against Each of the Four Vaccine Influenza Strains.", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Any fever was defined as any fever \u226538.0 \u00b0C irrespective of intensity and relationship to vaccination. Related was defined as symptoms considered by the investigator to have a causal relationship to vaccination. Grade 3 fever was defined as fever \u226539.0 \u00b0C.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of quadrivalent influenza GSK2282512A vaccine.\nQuadrivalent influenza GSK2282512A vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects \u2265 12 months of age).", 
                                    "title": "GSK2282512A Group"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Fluarix vaccine.\nFluarix vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects \u2265 12 months of age).", 
                                    "title": "Fluarix Group"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "290"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "296"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "46"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "42"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Any Fever"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "16"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "8"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Grade 3 Fever"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "39"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "38"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Related Fever"
                                            }
                                        ]
                                    }, 
                                    "description": "Any fever was defined as any fever \u226538.0 \u00b0C irrespective of intensity and relationship to vaccination. Related was defined as symptoms considered by the investigator to have a causal relationship to vaccination. Grade 3 fever was defined as fever \u226539.0 \u00b0C.", 
                                    "param": "Number", 
                                    "title": "Number of Subjects Reporting Any, Grade 3 and Related Fever", 
                                    "units": "subjects"
                                }
                            ]
                        }, 
                        "population": "The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented.", 
                        "safety_issue": "No", 
                        "time_frame": "During the 4-day (Days 0-3) post-vaccination period", 
                        "title": "Number of Subjects Reporting Any, Grade 3 and Related Fever", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "MAEs were defined as adverse events with medically-attended visits that were not routine visits for physical examination or vaccination, such as visits for hospitalization, an emergency room visit, or an otherwise unscheduled visit to or from medical personnel (medical doctor) for any reason. Any was defined as any occurrence of MAE(s).", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of quadrivalent influenza GSK2282512A vaccine.\nQuadrivalent influenza GSK2282512A vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects \u2265 12 months of age).", 
                                    "title": "GSK2282512A Group"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Fluarix vaccine.\nFluarix vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects \u2265 12 months of age).", 
                                    "title": "Fluarix Group"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "299"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "302"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "156"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "156"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "MAEs were defined as adverse events with medically-attended visits that were not routine visits for physical examination or vaccination, such as visits for hospitalization, an emergency room visit, or an otherwise unscheduled visit to or from medical personnel (medical doctor) for any reason. Any was defined as any occurrence of MAE(s).", 
                                    "param": "Number", 
                                    "title": "Number of Subjects Reporting Any Medically Attended Adverse Events (MAEs)", 
                                    "units": "subjects"
                                }
                            ]
                        }, 
                        "population": "The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented.", 
                        "safety_issue": "No", 
                        "time_frame": "During the entire study period (Day 0 to Day 180)", 
                        "title": "Number of Subjects Reporting Any Medically Attended Adverse Events (MAEs)", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Potential immune-mediated diseases (pIMDs) were defined as a subset of adverse events that included both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which might or might not have an autoimmune aetiology. Any pIMD was defined as at least one pIMD experienced by the study subject.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of quadrivalent influenza GSK2282512A vaccine.\nQuadrivalent influenza GSK2282512A vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects \u2265 12 months of age).", 
                                    "title": "GSK2282512A Group"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Fluarix vaccine.\nFluarix vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects \u2265 12 months of age).", 
                                    "title": "Fluarix Group"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "299"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "302"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "2"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Any pIMD(s)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "0"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "0"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Related pIMD(s)"
                                            }
                                        ]
                                    }, 
                                    "description": "Potential immune-mediated diseases (pIMDs) were defined as a subset of adverse events that included both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which might or might not have an autoimmune aetiology. Any pIMD was defined as at least one pIMD experienced by the study subject.", 
                                    "param": "Number", 
                                    "title": "Number of Subjects Reporting Any Potential Immune-Mediated Diseases (pIMDs)", 
                                    "units": "subjects"
                                }
                            ]
                        }, 
                        "population": "The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented.", 
                        "safety_issue": "No", 
                        "time_frame": "During the entire study period (Day 0 to Day 180)", 
                        "title": "Number of Subjects Reporting Any Potential Immune-Mediated Diseases (pIMDs)", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "An unsolicited AE was defined as an untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of quadrivalent influenza GSK2282512A vaccine.\nQuadrivalent influenza GSK2282512A vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects \u2265 12 months of age).", 
                                    "title": "GSK2282512A Group"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Fluarix vaccine.\nFluarix vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects \u2265 12 months of age).", 
                                    "title": "Fluarix Group"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "299"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "302"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "142"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "165"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Any Unsolicited AEs"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "9"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "5"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Grade 3 Unsolicited AEs"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "17"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "13"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Related Unsolicited AEs"
                                            }
                                        ]
                                    }, 
                                    "description": "An unsolicited AE was defined as an untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination.", 
                                    "param": "Number", 
                                    "title": "Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs).", 
                                    "units": "subjects"
                                }
                            ]
                        }, 
                        "population": "The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented.", 
                        "safety_issue": "No", 
                        "time_frame": "During the 28-day (Days 0-27) post-vaccination period.", 
                        "title": "Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs).", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "A serious adverse event was defined as any untoward medical occurrence that: resulted in death, was life threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of quadrivalent influenza GSK2282512A vaccine.\nQuadrivalent influenza GSK2282512A vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects \u2265 12 months of age).", 
                                    "title": "GSK2282512A Group"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Fluarix vaccine.\nFluarix vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects \u2265 12 months of age).", 
                                    "title": "Fluarix Group"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "299"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "302"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "9"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "8"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Any SAEs"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": [
                                                        {
                                                            "@group_id": "O1", 
                                                            "@value": "1"
                                                        }, 
                                                        {
                                                            "@group_id": "O2", 
                                                            "@value": "0"
                                                        }
                                                    ]
                                                }, 
                                                "sub_title": "Related SAEs"
                                            }
                                        ]
                                    }, 
                                    "description": "A serious adverse event was defined as any untoward medical occurrence that: resulted in death, was life threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.", 
                                    "param": "Number", 
                                    "title": "Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs)", 
                                    "units": "subjects"
                                }
                            ]
                        }, 
                        "population": "The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects with at least one vaccine administration documented.", 
                        "safety_issue": "No", 
                        "time_frame": "During the entire study period (Day 0 \u2013 Day 180)", 
                        "title": "Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs)", 
                        "type": "Secondary"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": [
                        {
                            "@group_id": "P1", 
                            "description": "Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of quadrivalent influenza GSK2282512A vaccine.\nQuadrivalent influenza GSK2282512A vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects \u2265 12 months of age).", 
                            "title": "GSK2282512A Group"
                        }, 
                        {
                            "@group_id": "P2", 
                            "description": "Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Fluarix vaccine.\nFluarix vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects \u2265 12 months of age).", 
                            "title": "Fluarix Group"
                        }
                    ]
                }, 
                "period_list": {
                    "period": {
                        "drop_withdraw_reason_list": {
                            "drop_withdraw_reason": [
                                {
                                    "participants_list": {
                                        "participants": [
                                            {
                                                "@count": "6", 
                                                "@group_id": "P1"
                                            }, 
                                            {
                                                "@count": "2", 
                                                "@group_id": "P2"
                                            }
                                        ]
                                    }, 
                                    "title": "Lost to Follow-up"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": [
                                            {
                                                "@count": "6", 
                                                "@group_id": "P1"
                                            }, 
                                            {
                                                "@count": "6", 
                                                "@group_id": "P2"
                                            }
                                        ]
                                    }, 
                                    "title": "Withdrawal by Subject"
                                }
                            ]
                        }, 
                        "milestone_list": {
                            "milestone": [
                                {
                                    "participants_list": {
                                        "participants": [
                                            {
                                                "@count": "299", 
                                                "@group_id": "P1"
                                            }, 
                                            {
                                                "@count": "302", 
                                                "@group_id": "P2"
                                            }
                                        ]
                                    }, 
                                    "title": "STARTED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": [
                                            {
                                                "#text": "Up to Day 180", 
                                                "@count": "287", 
                                                "@group_id": "P1"
                                            }, 
                                            {
                                                "#text": "Up to Day 180", 
                                                "@count": "294", 
                                                "@group_id": "P2"
                                            }
                                        ]
                                    }, 
                                    "title": "COMPLETED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": [
                                            {
                                                "@count": "12", 
                                                "@group_id": "P1"
                                            }, 
                                            {
                                                "@count": "8", 
                                                "@group_id": "P2"
                                            }
                                        ]
                                    }, 
                                    "title": "NOT COMPLETED"
                                }
                            ]
                        }, 
                        "title": "Overall Study"
                    }
                }, 
                "recruitment_details": "Primed subjects: Received 2 doses of seasonal influenza vaccine separated by at least one month during the last season or had received at least 1 dose prior to last season. Unprimed subjects: Did not receive any seasonal influenza vaccine in the past or received only 1 dose for the first time in the last influenza season."
            }, 
            "point_of_contact": {
                "name_or_title": "GSK Response Center", 
                "organization": "GlaxoSmithKline", 
                "phone": "866-435-7343"
            }, 
            "reported_events": {
                "desc": "For the systematically assessed other (non-serious) adverse events, the number of participants at risk included those from Total Vaccinated Cohort who had the symptom sheet completed.", 
                "group_list": {
                    "group": [
                        {
                            "@group_id": "E1", 
                            "description": "Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of quadrivalent influenza GSK2282512A vaccine.\nQuadrivalent influenza GSK2282512A vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects \u2265 12 months of age).", 
                            "title": "GSK2282512A Group"
                        }, 
                        {
                            "@group_id": "E2", 
                            "description": "Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Fluarix vaccine.\nFluarix vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects \u2265 12 months of age).", 
                            "title": "Fluarix Group"
                        }
                    ]
                }, 
                "other_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "118", 
                                                "@subjects_at_risk": "299"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "123", 
                                                "@subjects_at_risk": "302"
                                            }
                                        ], 
                                        "sub_title": "Total, other adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "assessment": "Non-systematic Assessment", 
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "38", 
                                                "@subjects_at_risk": "299"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "38", 
                                                "@subjects_at_risk": "302"
                                            }
                                        ], 
                                        "sub_title": "Diarrhoea"
                                    }
                                }, 
                                "title": "Gastrointestinal disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "95", 
                                                    "@subjects_at_risk": "299"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "91", 
                                                    "@subjects_at_risk": "302"
                                                }
                                            ], 
                                            "sub_title": "Pain"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "93", 
                                                    "@subjects_at_risk": "290"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "88", 
                                                    "@subjects_at_risk": "296"
                                                }
                                            ], 
                                            "sub_title": "Drowsiness"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "118", 
                                                    "@subjects_at_risk": "290"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "123", 
                                                    "@subjects_at_risk": "296"
                                                }
                                            ], 
                                            "sub_title": "Irritability/fussiness"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "99", 
                                                    "@subjects_at_risk": "290"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "100", 
                                                    "@subjects_at_risk": "296"
                                                }
                                            ], 
                                            "sub_title": "Loss of appetite"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "61", 
                                                    "@subjects_at_risk": "290"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "60", 
                                                    "@subjects_at_risk": "296"
                                                }
                                            ], 
                                            "description": "Assessed during the 7-day (Days 0-6) post-vaccination period", 
                                            "sub_title": "Fever"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "46", 
                                                    "@subjects_at_risk": "290"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "42", 
                                                    "@subjects_at_risk": "296"
                                                }
                                            ], 
                                            "description": "Assessed duringthe 4-day (Days 0-3) post-vaccination period", 
                                            "sub_title": "Fever"
                                        }
                                    ]
                                }, 
                                "title": "General disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "assessment": "Non-systematic Assessment", 
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "78", 
                                                "@subjects_at_risk": "299"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "90", 
                                                "@subjects_at_risk": "302"
                                            }
                                        ], 
                                        "sub_title": "Nasopharyngitis"
                                    }
                                }, 
                                "title": "Infections and infestations"
                            }
                        ]
                    }, 
                    "default_assessment": "Systematic Assessment", 
                    "frequency_threshold": "5"
                }, 
                "serious_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "9", 
                                                "@subjects_at_risk": "299"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "8", 
                                                "@subjects_at_risk": "302"
                                            }
                                        ], 
                                        "sub_title": "Total, serious adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "299"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "302"
                                                }
                                            ], 
                                            "sub_title": "Colitis ulcerative"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "299"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "302"
                                                }
                                            ], 
                                            "sub_title": "Diarrhoea"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "299"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "302"
                                                }
                                            ], 
                                            "sub_title": "Intestinal obstruction"
                                        }
                                    ]
                                }, 
                                "title": "Gastrointestinal disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "299"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "2", 
                                                    "@subjects_at_risk": "302"
                                                }
                                            ], 
                                            "sub_title": "Bronchiolitis"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "299"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "2", 
                                                    "@subjects_at_risk": "302"
                                                }
                                            ], 
                                            "sub_title": "Gastroenteritis rotavirus"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "299"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "302"
                                                }
                                            ], 
                                            "sub_title": "Amoebic dysentery"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "299"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "302"
                                                }
                                            ], 
                                            "sub_title": "Bacterial pyelonephritis"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "299"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "302"
                                                }
                                            ], 
                                            "sub_title": "Blastocystis infection"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "299"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "302"
                                                }
                                            ], 
                                            "sub_title": "Dengue fever"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "299"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "302"
                                                }
                                            ], 
                                            "sub_title": "Otitis media acute"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "299"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "302"
                                                }
                                            ], 
                                            "sub_title": "Peritonitis"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "299"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "302"
                                                }
                                            ], 
                                            "sub_title": "Pharyngitis streptococcal"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "299"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "302"
                                                }
                                            ], 
                                            "sub_title": "Respiratory syncytial virus bronchiolitis"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "299"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "302"
                                                }
                                            ], 
                                            "sub_title": "Rotavirus infection"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "299"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "302"
                                                }
                                            ], 
                                            "sub_title": "Septic shock"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "299"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "302"
                                                }
                                            ], 
                                            "sub_title": "Tonsillitis"
                                        }
                                    ]
                                }, 
                                "title": "Infections and infestations"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "299"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "302"
                                            }
                                        ], 
                                        "sub_title": "Dehydration"
                                    }
                                }, 
                                "title": "Metabolism and nutrition disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "299"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "302"
                                            }
                                        ], 
                                        "sub_title": "Febrile convulsion"
                                    }
                                }, 
                                "title": "Nervous system disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "299"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "302"
                                                }
                                            ], 
                                            "sub_title": "Asthma"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "299"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "302"
                                                }
                                            ], 
                                            "sub_title": "Bronchial hyperreactivity"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "299"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "302"
                                                }
                                            ], 
                                            "sub_title": "Pneumonia aspiration"
                                        }
                                    ]
                                }, 
                                "title": "Respiratory, thoracic and mediastinal disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Non-systematic Assessment"
                }, 
                "time_frame": "Serious Adverse Events: From Day 0 to Day 180; Solicited local and general symptoms: During the 7-day (Days 0-6) post-vaccination period; Unsolicited adverse events: During the 28-day (Days 0-27) post-vaccination period."
            }
        }, 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Influenza", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "detailed_description": {
            "textblock": "The subjects will be randomized (1:1) in the 2 treatment groups to explore responses to\n      vaccination in a sub-group analysis based on age (6 to 17 months, 18 to 35 months)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject's parent(s)/Legally Acceptable Representative(s) [LAR(s)] who, in the opinion\n             of the investigator, can and will comply with the requirements of the protocol.\n\n          -  A male or female between, and including, 6 and 35 months of age at the time of the\n             first vaccination.\n\n          -  Written informed consent obtained from the parent(s)/LAR(s) of the subject.\n\n          -  Subjects in stable health as determined by the investigator's clinical examination\n             and assessment of subject's medical history.\n\n          -  Subjects are eligible regardless of history of administration of influenza vaccine in\n             a previous season.\n\n        Exclusion Criteria:\n\n          -  Use of any investigational or non-registered product other than the study vaccine\n             within 30 days preceding the first dose of study vaccine, or planned use during the\n             study period. Routine registered childhood vaccinations are permitted.\n\n          -  Child in care.\n\n          -  Prior receipt of any seasonal or pandemic influenza vaccine within six months\n             preceding the first dose of study vaccine, or planned use during the study period.\n\n          -  Chronic administration of immunosuppressants or other immune-modifying drugs within\n             six months prior to the first vaccine dosed.\n\n          -  Administration of immunoglobulins and/or any blood products within the three months\n             preceding the first dose of study vaccine or planned administration during the study\n             period.\n\n          -  History of Guillain-Barr\u00e9 syndrome within six weeks of receipt of prior influenza\n             vaccine.\n\n          -  Any known or suspected allergy to any constituent of influenza vaccines; a history of\n             anaphylactic-type reaction to consumption of eggs; or a history of severe adverse\n             reaction to a previous influenza vaccine.\n\n          -  Acute disease and/or fever at the time of enrolment.\n\n          -  Any significant disorder of coagulation or treatment with warfarin derivatives or\n             heparin.\n\n          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on\n             medical history and physical examination.\n\n          -  Any other condition which, in the opinion of the investigator, prevents the subject\n             from participating in the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "35 Months", 
            "minimum_age": "6 Months"
        }, 
        "enrollment": {
            "#text": "606", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 18, 2012", 
        "firstreceived_results_date": "February 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01711736", 
            "org_study_id": "116926"
        }, 
        "intervention": [
            {
                "arm_group_label": "GSK2282512A Group", 
                "description": "1 or 2 doses administered intramuscularly (IM) in deltoid muscle or anterolateral thigh on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects) respectively.", 
                "intervention_name": "Quadrivalent influenza GSK2282512A vaccine", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Fluarix Group", 
                "description": "1 or 2 doses administered IM in deltoid muscle or anterolateral thigh, on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects) respectively.", 
                "intervention_name": "Fluarix", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Immunogenicity", 
            "Children", 
            "Safety", 
            "Seasonal influenza", 
            "Fluarix"
        ], 
        "lastchanged_date": "February 20, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Halifax", 
                        "country": "Canada", 
                        "state": "Nova Scotia", 
                        "zip": "B3K 6R8"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brampton", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L6T 0G1"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamilton", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L8L 5G8"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sudbury", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "P3E 1H5"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mirabel", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "J7J 2K8"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Qu\u00e9bec City", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "G1E 7G9"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santo Domingo, Distrito Nacional", 
                        "country": "Dominican Republic"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Pedro Sula", 
                        "country": "Honduras"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Canada", 
                "Dominican Republic", 
                "Honduras"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) When Administered in Children", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Canada: Biologics and Genetic Therapies Directorate (BGTD)"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "A seroconverted subject was defined as a vaccinated subject with either a pre-vaccination titer less than (<) 1:10 and a post-vaccination titer greater than or equal to (\u2265) 1:40, or a pre-vaccination titer \u2265 1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains assessed were Flu A/CAL/7/09 (H1N1), Flu A/Victoria/361/11 (H3N2), Flu B/Hubei-Wujiagang/158/09 (Yamagata) and Flu B/Bri/60/08 (Victoria). This outcome concerns solely subjects in the GSK2282512A Group.", 
                "measure": "Number of Seroconverted Subjects for Anti- Haemagglutination Inhibition (HI) Antibodies Against Each of the Four Vaccine Influenza Strains of Quadrivalent Influenza GSK2282512A Vaccine.", 
                "safety_issue": "No", 
                "time_frame": "At Day 28 for primed subjects and at Day 56 for unprimed subjects"
            }, 
            {
                "description": "Solicited local symptoms assessed were pain, redness and swelling. Any was defined as occurrence of the specified solicited local symptom regardless of its intensity. Grade 3 pain was defined as pain that prevented normal everyday activities. Grade 3 swelling was greater than 100 millimeters (mm) i.e. >100mm.", 
                "measure": "Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms.", 
                "safety_issue": "No", 
                "time_frame": "During the 7-day (Days 0-6) post-vaccination period"
            }, 
            {
                "description": "Solicited general symptoms assessed were drowsiness, irritability/fussiness and loss of appetite. Any was defined as any solicited general symptom reported irrespective of intensity and relationship to vaccination. Related was defined as symptoms assessed by the investigator to have a causal relationship to vaccination. Grade 3 irritability/fussiness was defined as crying that could not be comforted/prevented normal activity. Grade 3 loss of appetite was defined as not eating at all. Grade 3 drowsiness was defined as drowsiness that prevented normal activity.", 
                "measure": "Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms (Excluding Fever).", 
                "safety_issue": "No", 
                "time_frame": "During the 7-day (Days 0-6) post-vaccination period"
            }, 
            {
                "description": "Any fever was defined as any fever \u226538.0 degrees Celsius (\u00b0C) irrespective of intensity and relationship to vaccination. Related was defined as symptoms assessed by the investigator to have a causal relationship to vaccination. Grade 3 fever was defined as fever \u226539.0 \u00b0C.", 
                "measure": "Number of Subjects Reporting Any, Grade 3 and Related Fever", 
                "safety_issue": "No", 
                "time_frame": "During the 7-day (Days 0-6) post-vaccination period"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01711736"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "HI antibody titres were expressed as Geometric mean titers (GMTs). The vaccine strains assessed were Flu A/CAL/7/09 (H1N1), Flu A/Victoria/361/11 (H3N2), Flu B/Hubei-Wujiagang/158/09 (Yamagata) and Flu B/Bri/60/08 (Victoria)", 
                "measure": "Haemagglutination Inhibition (HI) Antibody Titers Against Each of the Four Vaccine Influenza Strains", 
                "safety_issue": "No", 
                "time_frame": "At Day 0 (for all subjects) and 28 days after the last vaccine dose (at Day 28 for primed subjects and at Day 56 for unprimed subjects)"
            }, 
            {
                "description": "A seroconverted subject was defined as a vaccinated subject with either a pre-vaccination titer less than (<) 1:10 and a post-vaccination titer greater than or equal to (\u2265) 1:40, or a pre-vaccination titer \u2265 1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains assessed were Flu A/CAL/7/09 (H1N1), Flu A/Victoria/361/11 (H3N2), Flu B/Hubei-Wujiagang/158/09 (Yamagata) and Flu B/Bri/60/08 (Victoria). This outcome concerns solely subjects in the Fluarix Group.", 
                "measure": "Number of Seroconverted Subjects for Anti- Haemagglutination Inhibition (HI) Antibodies Against Each of the Four Vaccine Influenza Strains of Fluarix Vaccine", 
                "safety_issue": "No", 
                "time_frame": "At Day 28 for primed subjects and at Day 56 for unprimed subjects"
            }, 
            {
                "description": "A seroprotected subject was defined as a vaccinated subject with a serum HI titer greater than or equal to (\u2265) 1:40 that usually is accepted as indicating protection in adults. The vaccine strains assessed were Flu A/CAL/7/09 (H1N1), Flu A/Victoria/361/11 (H3N2), Flu B/Hubei-Wujiagang/158/09 (Yamagata) and Flu B/Bri/60/08 (Victoria)", 
                "measure": "Number of Subjects Who Were Seroprotected for Haemagglutination Inhibition (HI) Antibodies Against Each of the Four Vaccine Influenza Strains.", 
                "safety_issue": "No", 
                "time_frame": "At Day 0 (for all subjects) and Day 28 after last vaccine dose (Day 28 for primed subjects and Day 56 for unprimed subjects)"
            }, 
            {
                "description": "MGI was defined as the fold increase in serum haemagglutination inhibition (HI) GMTs post-vaccination compared to pre-vaccination (Day 0). The vaccine strains assessed were Flu A/CAL/7/09 (H1N1), Flu A/Victoria/361/11 (H3N2), Flu B/Hubei-Wujiagang/158/09 (Yamagata) and Flu B/Bri/60/08 (Victoria)", 
                "measure": "Mean Geometric Increase (MGI) for Haemagglutination Inhibition (HI) Antibody Titer Against Each of the Four Vaccine Influenza Strains.", 
                "safety_issue": "No", 
                "time_frame": "28 days after the last vaccine dose (at Day 28 for primed subjects and at Day 56 for unprimed subjects)"
            }, 
            {
                "description": "Any fever was defined as any fever \u226538.0 \u00b0C irrespective of intensity and relationship to vaccination. Related was defined as symptoms considered by the investigator to have a causal relationship to vaccination. Grade 3 fever was defined as fever \u226539.0 \u00b0C.", 
                "measure": "Number of Subjects Reporting Any, Grade 3 and Related Fever", 
                "safety_issue": "No", 
                "time_frame": "During the 4-day (Days 0-3) post-vaccination period"
            }, 
            {
                "description": "MAEs were defined as adverse events with medically-attended visits that were not routine visits for physical examination or vaccination, such as visits for hospitalization, an emergency room visit, or an otherwise unscheduled visit to or from medical personnel (medical doctor) for any reason. Any was defined as any occurrence of MAE(s).", 
                "measure": "Number of Subjects Reporting Any Medically Attended Adverse Events (MAEs)", 
                "safety_issue": "No", 
                "time_frame": "During the entire study period (Day 0 to Day 180)"
            }, 
            {
                "description": "Potential immune-mediated diseases (pIMDs) were defined as a subset of adverse events that included both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which might or might not have an autoimmune aetiology. Any pIMD was defined as at least one pIMD experienced by the study subject.", 
                "measure": "Number of Subjects Reporting Any Potential Immune-Mediated Diseases (pIMDs)", 
                "safety_issue": "No", 
                "time_frame": "During the entire study period (Day 0 to Day 180)"
            }, 
            {
                "description": "An unsolicited AE was defined as an untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination.", 
                "measure": "Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs).", 
                "safety_issue": "No", 
                "time_frame": "During the 28-day (Days 0-27) post-vaccination period."
            }, 
            {
                "description": "A serious adverse event was defined as any untoward medical occurrence that: resulted in death, was life threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.", 
                "measure": "Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs)", 
                "safety_issue": "No", 
                "time_frame": "During the entire study period (Day 0 - Day 180)"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}